Bahl & Gaynor LLC Sells 30,183 Shares of Amgen Inc. $AMGN

Bahl & Gaynor LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 156,410 shares of the medical research company’s stock after selling 30,183 shares during the quarter. Bahl & Gaynor LLC’s holdings in Amgen were worth $65,928,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp boosted its position in Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. MW Advisory LLC purchased a new stake in shares of Amgen during the 2nd quarter valued at about $1,054,000. Baird Financial Group Inc. increased its position in shares of Amgen by 1.6% during the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after purchasing an additional 5,496 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Amgen by 105.8% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock valued at $5,696,000 after purchasing an additional 6,947 shares during the last quarter. Finally, Nilsine Partners LLC bought a new position in shares of Amgen in the 2nd quarter worth approximately $3,329,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

AMGN opened at $465.23 on Wednesday. The company has a 50 day simple moving average of $423.79 and a two-hundred day simple moving average of $379.39. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The firm has a market cap of $251.65 billion, a P/E ratio of 20.07, a PEG ratio of 3.25 and a beta of 0.43. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same period last year, the firm earned $5.64 EPS. The company’s revenue was up 8.5% on a year-over-year basis. Equities analysts forecast that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is presently 58.47%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AMGN. Citigroup raised their price objective on shares of Amgen from $405.00 to $465.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. BMO Capital Markets reduced their target price on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a report on Monday, October 12th. Sanford C. Bernstein increased their price target on shares of Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a research report on Wednesday, November 4th. HSBC downgraded shares of Amgen from a “buy” rating to a “hold” rating and decreased their price target for the stock from $445.00 to $425.00 in a research report on Thursday, September 10th. Finally, Argus lifted their price target on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $422.76.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.